CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Inje cocktail +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04201197
NCT04201197Phase 1Completed
CompareCT.gov

Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs

Johns Hopkins University·interventional·Posted Dec 17, 2019·Updated Jul 24, 2023

In Brief

A Phase 1 clinical trial evaluating Inje cocktail, THC Cannabis extract, and 1 other intervention for Drug-Interactions. Completed, enrolled 22 participants across 1 site.

Detailed Summary

This study will evaluate drug-drug interactions between cannabis extracts containing Tetrahydrocannabinol (THC) and THC+ Cannabinoids (CBD) and probe drugs for select CYP450 pathways including: caffeine (CYP1A2), omeprazole (CYP2C19), losartan (CYP2C9), dextromethorphan (CYP2D6), and midazolam (CYP3A).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug-Interactions
CountriesUnited States
CollaboratorsWashington State University, National Center for Complementary and Integrative Health (NCCIH)

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedDec 17, 2019
Enrollment StartNov 10, 2020
Primary CompletionMar 16, 2022
Study CompletionJul 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.5 years ago

Interventions

Inje cocktaildrug

Acute drug exposure

THC Cannabis extractdrug

Acute drug exposure

THC/CBD Cannabis Extractdrug

Acute drug exposure